Condition (MeSH)
Cell Transformation, Neoplastic
ClinicalTrials.gov lists 355 trials for Cell Transformation, Neoplastic or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 40.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
2 more sections with rows
When did Cell Transformation, Neoplastic trials start? (34)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
- Other (Expanded access, Unknown)
Top of scale: 29
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2022 | 2 |
| 2021 | 1 |
| 2020 | 6 |
| 2019 | 1 |
| 2018 | 6 |
| 2017 | 4 |
| 2016 | 2 |
| 2015 | 5 |
Showing 10 of 34 earlier years.
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 43 months across 290 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Cell Transformation, Neoplastic trials in? (10)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 108 |
| Phase 1/2 | 41 |
| Phase 2 | 115 |
| Phase 2/3 | 2 |
| Phase 3 | 24 |
| Phase 4 | 3 |
| Not applicable | 32 |
| Observational | 26 |
| Expanded access | 3 |
| Unknown | 1 |
How many Cell Transformation, Neoplastic trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 11 |
| Active, not recruiting | 9 |
| Completed | 251 |
| Approved for marketing | 1 |
| Terminated | 60 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Cell Transformation, Neoplastic trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 40 |
| Novartis Pharmaceuticals | 6 |
Which drugs are being tested for Cell Transformation, Neoplastic? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cytoxan | 64 |
| Busulfan | 43 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| SQ Fludarabine | 61 |
| Peripheral blood stem cell transplantation | 58 |
| IR Tacrolimus | 39 |
| HD- Methotrexate (MTX) | 38 |
| Allogeneic (Allo) hematopoietic stem cell transplantation | 37 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Cell Transformation, Neoplastic trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Death | 217 | 9 |
| 1 yr TRM | 93 | 1 |
| Febrile neutropenia | 65 | 11 |
| Infections and infestations - Other | 50 | 2 |
| Mucositis oral | 48 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Cell Transformation, Neoplastic? (622)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Lung adenocarcinoma promotion by air pollutants. | Nature | 2023 | Yes |
| Rho GTPase signaling in cancer progression and dissemination. | Physiological reviews | 2022 | Yes |
| Gut microbiota influence tumor development and Alter interactions with the human immune system. | Journal of experimental & clinical cancer research : CR | 2021 | Yes |
| The Use of Human Serum Samples to Study Malignant Transformation: A Pilot Study. | Cells | 2021 | Yes |
| Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: <sup>64</sup>Cu- and <sup>225</sup>Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2020 | Yes |
Showing 5 of 622 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.